Literature DB >> 34633646

Direct Oral Anticoagulants and Warfarin for Atrial Fibrillation Treatment: Rural and Urban Trends in Medicare Beneficiaries.

Faye L Norby1,2, Pamela L Lutsey3, Nathan D Shippee4, Lin Y Chen5, Carrie Henning-Smith4,6, Alvaro Alonso7, Rob F Walker3, Aaron R Folsom3.   

Abstract

BACKGROUND: Data are needed on the use of oral anticoagulation in patients with atrial fibrillation (AF) in rural versus urban areas, including the initiation of direct oral anticoagulants (DOACs).
OBJECTIVE: We used Medicare data to examine rural/urban differences in anticoagulation use in patients with AF.
METHODS: We identified incident AF in a 20% sample of fee-for-service Medicare beneficiaries (aged ≥ 65 years) from 2011 to 2016 and collected ZIP code and covariates at the time of AF. We identified the first anticoagulant prescription filled, if any, following AF diagnosis. We categorized beneficiaries into four rural/urban areas using rural-urban commuting area codes and used Poisson regression models to compare anticoagulant use.
RESULTS: We included 447,252 patients with AF (mean age 79 ± 8 years), of which 82% were urban, 9% large rural, 5% small rural, and 4% isolated. The percentage who initiated an anticoagulant rose from 34% in 2011 to 53% in 2016, paralleling the uptake of DOACs. In a multivariable-adjusted analysis, those in rural areas (vs. urban) were more likely to initiate an anticoagulant. However, rural beneficiaries (vs. urban) were less likely to initiate a DOAC; those in isolated areas were 17% less likely (95% confidence interval [CI] 13-20), those in small rural areas were 12% less likely (95% CI 9-15), and those in large rural areas were 10% less likely (95% CI 8-12).
CONCLUSION: Among Medicare beneficiaries with AF, anticoagulation use was low but increased over time with the introduction of DOACs. Rural beneficiaries were less likely to receive a DOAC.
© 2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34633646     DOI: 10.1007/s40256-021-00502-9

Source DB:  PubMed          Journal:  Am J Cardiovasc Drugs        ISSN: 1175-3277            Impact factor:   3.283


  23 in total

1.  Patterns of initiation of oral anticoagulants in patients with atrial fibrillation- quality and cost implications.

Authors:  Nihar R Desai; Alexis A Krumme; Sebastian Schneeweiss; William H Shrank; Gregory Brill; Edmund J Pezalla; Claire M Spettell; Troyen A Brennan; Olga S Matlin; Jerry Avorn; Niteesh K Choudhry
Journal:  Am J Med       Date:  2014-05-21       Impact factor: 4.965

2.  2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.

Authors:  Craig T January; L Samuel Wann; Hugh Calkins; Lin Y Chen; Joaquin E Cigarroa; Joseph C Cleveland; Patrick T Ellinor; Michael D Ezekowitz; Michael E Field; Karen L Furie; Paul A Heidenreich; Katherine T Murray; Julie B Shea; Cynthia M Tracy; Clyde W Yancy
Journal:  J Am Coll Cardiol       Date:  2019-01-28       Impact factor: 24.094

3.  Rural-urban disparities in the prevalence of diabetes and coronary heart disease.

Authors:  A O'Connor; G Wellenius
Journal:  Public Health       Date:  2012-08-24       Impact factor: 2.427

Review 4.  A systematic review of validated methods for identifying atrial fibrillation using administrative data.

Authors:  Paul N Jensen; Karin Johnson; James Floyd; Susan R Heckbert; Ryan Carnahan; Sascha Dublin
Journal:  Pharmacoepidemiol Drug Saf       Date:  2012-01       Impact factor: 2.890

5.  2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society.

Authors:  Craig T January; L Samuel Wann; Joseph S Alpert; Hugh Calkins; Joaquin E Cigarroa; Joseph C Cleveland; Jamie B Conti; Patrick T Ellinor; Michael D Ezekowitz; Michael E Field; Katherine T Murray; Ralph L Sacco; William G Stevenson; Patrick J Tchou; Cynthia M Tracy; Clyde W Yancy
Journal:  Circulation       Date:  2014-03-28       Impact factor: 29.690

6.  National Trends in Ambulatory Oral Anticoagulant Use.

Authors:  Geoffrey D Barnes; Eleanor Lucas; G Caleb Alexander; Zachary D Goldberger
Journal:  Am J Med       Date:  2015-07-02       Impact factor: 4.965

7.  Incidence and prevalence of atrial fibrillation and associated mortality among Medicare beneficiaries, 1993-2007.

Authors:  Jonathan P Piccini; Bradley G Hammill; Moritz F Sinner; Paul N Jensen; Adrian F Hernandez; Susan R Heckbert; Emelia J Benjamin; Lesley H Curtis
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2012-01-10

8.  Prospective study of oral anticoagulants and risk of liver injury in patients with atrial fibrillation.

Authors:  Alvaro Alonso; Richard F MacLehose; Lin Y Chen; Lindsay Gs Bengtson; Alanna M Chamberlain; Faye L Norby; Pamela L Lutsey
Journal:  Heart       Date:  2017-01-05       Impact factor: 5.994

9.  Race, rural residence, and control of diabetes and hypertension.

Authors:  Arch G Mainous; Dana E King; David R Garr; William S Pearson
Journal:  Ann Fam Med       Date:  2004 Nov-Dec       Impact factor: 5.166

10.  Leading Causes of Death in Nonmetropolitan and Metropolitan Areas- United States, 1999-2014.

Authors:  Ernest Moy; Macarena C Garcia; Brigham Bastian; Lauren M Rossen; Deborah D Ingram; Mark Faul; Greta M Massetti; Cheryll C Thomas; Yuling Hong; Paula W Yoon; Michael F Iademarco
Journal:  MMWR Surveill Summ       Date:  2017-01-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.